Earth Science Tech, Inc. (ETST) Anticipates Uplist
Post# of 333
(Total Views: 209)
Posted On: 09/10/2018 3:49:54 PM
Earth Science Tech, Inc. (ETST) Anticipates Uplisting to OTCQB Venture Market after Achieving Fully Reporting Status with SEC
- With its Form 10 registration statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements to the SEC, as well as other obligations
- Biotech company is focused on the cannabidiol (CBD), pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research
- ETST develops innovative products with the goal of becoming a world leader in the CBD space; three new CBD formulas are being developed under a provisory patent
Earth Science Tech, Inc. (OTC: ETST) anticipates uplisting to the OTCQB Venture Market after receiving a Form 10 registration statement filing date. The biotech company will begin filing annual reports with the SEC on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K. Additional reporting obligations include shareholder actions, proxies and stock ownership rules (http://nnw.fm/pDC4Y).
In a news release, Nickolas S. Tabraue, president, chairman and director of ETST, said, “With our Form 10 filing now effective, ETST is progressing towards fulfilling its goals. Following this achievement, we anticipate to up-list to the OTCQB tier in early September, due to our early application submission with OTC Markets Group, Inc. We look forward to maximizing the value of our company for our loyal shareholders as we unfold.”
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils.
In Canada, it is testing three new CBD IP formulations. It is also testing its Hygee MSN-2 medical device, for the detection of sexually transmitted infections (STIs) in women, at Québec’s Clinique Santé Amitié (http://nnw.fm/g4vqP).
The company is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories. In the U.S., ETST is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on breast cancer and immune cells (http://nnw.fm/gJqL6).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. The company also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- With its Form 10 registration statement filing now effective, ETST will begin reporting annual, quarterly and periodic financial statements to the SEC, as well as other obligations
- Biotech company is focused on the cannabidiol (CBD), pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research
- ETST develops innovative products with the goal of becoming a world leader in the CBD space; three new CBD formulas are being developed under a provisory patent
Earth Science Tech, Inc. (OTC: ETST) anticipates uplisting to the OTCQB Venture Market after receiving a Form 10 registration statement filing date. The biotech company will begin filing annual reports with the SEC on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K. Additional reporting obligations include shareholder actions, proxies and stock ownership rules (http://nnw.fm/pDC4Y).
In a news release, Nickolas S. Tabraue, president, chairman and director of ETST, said, “With our Form 10 filing now effective, ETST is progressing towards fulfilling its goals. Following this achievement, we anticipate to up-list to the OTCQB tier in early September, due to our early application submission with OTC Markets Group, Inc. We look forward to maximizing the value of our company for our loyal shareholders as we unfold.”
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils.
In Canada, it is testing three new CBD IP formulations. It is also testing its Hygee MSN-2 medical device, for the detection of sexually transmitted infections (STIs) in women, at Québec’s Clinique Santé Amitié (http://nnw.fm/g4vqP).
The company is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories. In the U.S., ETST is conducting studies with the University of Central Oklahoma on the impact of high grade full spectrum CBD on breast cancer and immune cells (http://nnw.fm/gJqL6).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. The company also formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)